Please login to the form below

Not currently logged in
Email:
Password:

Novartis US appeals halt generic Famvir

Novartis says that a US court halted Israeli-based Teva's sale of a generic version of its Famvir genital herpes treatment

Novartis has said that that a US court has halted Israeli-based Teva's sale of a generic version of its Famvir (famciclovir) genital herpes treatment.

The Swiss-headquartered company said the injunction by the US Court of Appeals for the Federal Circuit was issued on 8 September, two days after a district court in New Jersey denied Novartis' motion to stop Israel's Teva from marketing its version of the drug.

The injunction requires Teva to submit a response by 11 September 2007, Novartis revealed in a company statement.

Novartis shares were down 0.4 per cent at CHF 63.25 (USD 53.27) on the Zurich stock exchange on 10 September 2007.

10th September 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics